Propanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor Conference

Wednesday & Thursday, November 9 – 10, 2022

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc’s Chief Executive Officer and Co-Founder, will conduct investor meetings and present at the upcoming Sidoti & Company’s upcoming Micro-Cap Virtual Investor Conference, which will be held on Wednesday and Thursday, November 9 – 10, 2022.

Mr. Nathanielsz will deliver his corporate presentation on Wednesday, November 9, at 4:00pm, Eastern Standard Time.

The Sidoti & Company Micro-Cap Investor Conference is a virtual event featuring dynamic, micro-cap companies interacting with a number of institutional investors from across the United States. Sidoti & Company is a provider of independent securities research focused on small and micro-cap companies and the institutions that invest in their securities. Their investor conferences have emerged as a leading forum for interaction between issuers and investors in the small and micro-cap investment community.

“The demand for innovative healthcare companies by institutional investors to present at the upcoming Sidoti & Company Micro-Cap Conference led to an exciting opportunity for Propanc to present the latest developments of our lead product candidate, PRP, as we advance towards a First-In-Human study in advanced cancer patients suffering from solid tumors,” said Mr. Nathanielsz. “I look forward to demonstrating how PRP treats and prevents metastatic cancer by targeting and eradicating cancer stem cells, free from side effects associated with standard treatment approaches. Furthermore, we recently announced potential future clinical applications in conjunction with our joint research partners, where PRP alters the tumor microenvironment. This means pre-treating tumors which are chemo-resistant so that they are susceptible to standard therapies once again.”

PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine and skin cancers.

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. For more information, please visit www.propanc.com.

The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.

To view the Company’s “Mechanism of Action” video on its anti-cancer lead product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These factors include uncertainties as to the Company’s ability to continue as a going concern absent new debt or equity financings; the Company’s current reliance on substantial debt financing that it is unable to repay in cash; the Company’s ability to successfully remediate material weaknesses in its internal controls; the Company’s ability to reach research and development milestones as planned and within proposed budgets; the Company’s ability to control costs; the Company’s ability to obtain adequate new financing on reasonable terms; the Company’s ability to successfully initiate and complete clinical trials and its ability to successful develop PRP, its lead product candidate; the Company’s ability to obtain and maintain patent protection; the Company’s ability to recruit employees and directors with accounting and finance expertise; the Company’s dependence on third parties for services; the Company’s dependence on key executives; the impact of government regulations, including FDA regulations; the impact of any future litigation; the availability of capital; changes in economic conditions, competition; and other risks, including, but not limited to, those described in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website at http://www.sec.gov. These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221026005460/en/